Our research consortium is dedicated to introduce most sophisticated analytical methods such as MALDI-MS Imaging
into clinical research and ultimately for the improvement of patient diagnostics and treatment. The research group consists
of clinicians (Prof. B. Gerber, department for obstetrics and gynecology, and Prof. O. Hakenberg, department of urology),
of pathologists (Prof. A. Erbersdobler, institute of pathology), the local biobank (Prof. G. Hildebrandt, Comprehensive Cancer Center
of the University of Rostock), and of experts in immunology (Prof. H.-J. Thiesen, institute of immunology) and mass
spectrometry and proteome research (Prof. M.O. Glocker, Proteome Center Rostock).
With this strategic alliance of experts we aim at developing standard operating procedures (SOPs) for the implementation
of MALDI-MS Imaging methods into clinical cancer research efforts and, equally imortant, to improve the current situation in
cancer diagnostics, and even prognostics. Starting with current state-of-the-art immunohistochemistry (Prof. A. Erbersdobler)
and sophisticated computer-assisted microscopy image analysis (Prof. H.-J. Thiesen),
the Proteome Center Rostock (Prof. M.O. Glocker) has developed in a pilot study a strategy for defining proteome signatures that
are to be evaluated as potential cancer signatures. The experiences made on breast cancer (in collaboration
with Prof. B. Gerber) shall now be transferred to other clinics with related but different application areas,
beginning with kidney cancer (Prof. O. Hakenberg). In parallel we aim at including the local biobank
of the Comprehensive Cancer Center of the University of Rostock (Prof. G. Hildebrandt) in order to make
MALDI-MS Imaging applications available for further cancer research fields.